The USA-based Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases.
This volume takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease, which is expected to affect more than 13.8 million people in the United States by 2050 and cost well over $1 trillion annually.
”The growing health and financial impact of Alzheimer’s disease on American patients, caregivers, and our healthcare system makes the need for new treatments more pressing each day,” said BIO president and chief executive Jim Greenwood, adding: “The good news is that America’s biopharmaceutical companies currently are conducting 74 clinical-stage programs intended to stop, prevent, or slow the progression of this looming crisis. The bad news is that, while these programs hold real promise, the R&D challenges with this disease are enormous and the level of investment and innovation is not where our nation needs it to be to address this exploding public health crisis. To win this fight, it is essential that our public policies stimulate more investment in research and innovation.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze